Literature DB >> 23291381

Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection.

Erdem Akbal1, Seyfettin Köklü, Erdem Koçak, Başak Cakal, Fahri Güneş, Omer Başar, Yaşar Tuna, Mehmet Senes.   

Abstract

BACKGROUND AND AIMS: Liver fatty acid-binding protein (L-FABP) is a small molecule. The aim of this study was to examine L-FABP levels and to detect its diagnostic value in chronic hepatitis C (CHC).
METHODS: We studied 22 patients with CHC and 20 healthy control subjects. Patients with persistently elevated serum aminotransferases and positive HCV RNA were included in the study. Patients with CHC underwent percutaneous liver biopsy. Serum level of L-FABP was determined by ELISA method.
RESULTS: Patients with CHC had significantly increased levels of L-FABP compared to controls. A strong correlation between serum L-FABP concentrations and aspartate aminotransferases, alanine aminotransferases, HCV RNA levels and hepatic inflammation was found. When a cut-off value was 29,000 pg/mL for L-FABP, sensitivity and specificity were 75 and 100%, respectively. Positive and negative predictive values for L-FABP were 100 and 78%, respectively.
CONCLUSIONS: Serum L-FABP is used as a new diagnostic marker to detect liver injury.
Copyright © 2013 IMSS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291381     DOI: 10.1016/j.arcmed.2012.11.007

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  15 in total

1.  Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.

Authors:  Constantine J Karvellas; Jaime L Speiser; Mélanie Tremblay; William M Lee; Christopher F Rose
Journal:  Hepatology       Date:  2017-01-19       Impact factor: 17.425

2.  Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Hikmetullah Batgi; Mehmet Şenes
Journal:  Wien Klin Wochenschr       Date:  2014-12-02       Impact factor: 1.704

3.  Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.

Authors:  Yun Zhang; Kechun Liu; Hozeifa M Hassan; Hongli Guo; Pingping Ding; Liwen Han; Qiuxia He; Weiyun Chen; Chung-Der Hsiao; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 4.  Metabolic functions of FABPs--mechanisms and therapeutic implications.

Authors:  Gökhan S Hotamisligil; David A Bernlohr
Journal:  Nat Rev Endocrinol       Date:  2015-08-11       Impact factor: 43.330

5.  The Importance of Liver-Fatty Acid Binding Protein in Diagnosis of Liver Damage in Patients with Acute Hepatitis.

Authors:  Ozlem Ozer Cakir; Aysun Toker; Huseyin Ataseven; Ali Demir; Hakki Polat
Journal:  J Clin Diagn Res       Date:  2017-04-01

6.  Adipocyte Fatty Acid-Binding Protein as a Predictor of Outcome in Alcohol-induced Acute-On-Chronic Liver Failure.

Authors:  Anand V Kulkarni; Mithun Sharma; Pramod Kumar; Venu Simhadri; Tirumalige R Sowmya; Sasikala Mitnala; Duvvuru Nageshwar Reddy; Padaki Nagaraja Rao
Journal:  J Clin Exp Hepatol       Date:  2020-07-28

7.  Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6.

Authors:  Hyunwoo Kim; Gaae Gil; Siyoung Lee; Areum Kwak; Seunghyun Jo; Ensom Kim; Tam T Nguyen; Sinae Kim; Hyunjhung Jhun; Somi Kim; Miyeon Kim; Youngmin Lee; Soohyun Kim
Journal:  Immune Netw       Date:  2016-10-25       Impact factor: 6.303

Review 8.  Drug-induced liver injury: recent advances in diagnosis and risk assessment.

Authors:  Gerd A Kullak-Ublick; Raul J Andrade; Michael Merz; Peter End; Andreas Benesic; Alexander L Gerbes; Guruprasad P Aithal
Journal:  Gut       Date:  2017-03-23       Impact factor: 23.059

9.  Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  Yung-Chuan Lu; Chi-Chang Chang; Chao-Ping Wang; Wei-Chin Hung; I-Ting Tsai; Wei-Hua Tang; Cheng-Ching Wu; Ching-Ting Wei; Fu-Mei Chung; Yau-Jiunn Lee; Chia-Chang Hsu
Journal:  Int J Med Sci       Date:  2020-01-14       Impact factor: 3.738

10.  Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Authors:  Maria Mikus; Kimi Drobin; Marcus Gry; Julie Bachmann; Johan Lindberg; Getnet Yimer; Eleni Aklillu; Eyasu Makonnen; Getachew Aderaye; James Roach; Ian Fier; Caroline Kampf; Jens Göpfert; Hugo Perazzo; Thierry Poynard; Camilla Stephens; Raúl J Andrade; M Isabel Lucena; Nadir Arber; Mathias Uhlén; Paul B Watkins; Jochen M Schwenk; Peter Nilsson; Ina Schuppe-Koistinen
Journal:  Liver Int       Date:  2016-06-22       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.